Naringenin decreases total cell viability. by Lauren A. Eanes (20995499)

Loss of Vps34 is associated with decreased eTreg survival but intact activation. by Erienne G. Norton (9612079)

Subjects:

Baseline patient characteristics. by Oscar F. C. van den Bosch (22184246)

“…In contrast, s-ketamine largely preserved respiratory variability, suggesting it may be a safer alternative for sedation in patients with impaired spontaneous breathing. Further studies are needed to assess the clinical implications of these observations in patients undergoing sedation.…”

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Decreased production of antiviral factors in patients infected with SARS-CoV-2 due to reduced TLR7 expression by Julia Cataldo Lima (22811497)

“…A decrease in pattern recognition receptors (PRRs) was also observed at both the gene and protein levels. …”

High-Temperature Resistance, Lightweight, and Thermally Insulating Silica Aerogel via Doping Hollow Silica Nanoparticles by Mingyang Yang (1405321)

Subjects:

High-Temperature Resistance, Lightweight, and Thermally Insulating Silica Aerogel via Doping Hollow Silica Nanoparticles by Mingyang Yang (1405321)

Subjects:

High-Temperature Resistance, Lightweight, and Thermally Insulating Silica Aerogel via Doping Hollow Silica Nanoparticles by Mingyang Yang (1405321)

Subjects:

High-Temperature Resistance, Lightweight, and Thermally Insulating Silica Aerogel via Doping Hollow Silica Nanoparticles by Mingyang Yang (1405321)

Subjects:

High-Temperature Resistance, Lightweight, and Thermally Insulating Silica Aerogel via Doping Hollow Silica Nanoparticles by Mingyang Yang (1405321)

Subjects:

High-Temperature Resistance, Lightweight, and Thermally Insulating Silica Aerogel via Doping Hollow Silica Nanoparticles by Mingyang Yang (1405321)

Subjects:

Patient demographics. by Tuğba Kocahan (21246715)

Subjects:

Patient characteristics and procedural data. by Jonathan Nadjiri (665209)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Percentage of positive responses to overall satisfaction 2011/12 by A) Age and sex B) SIMD decile C) Number of Health Issues and D) Urban/Rural Class. by David Henderson (4612354)

Subjects:

Percentage of positive responses to access question 2011/12 by A) Age and sex B) SIMD decile C) Number of Health Issues and D) Urban/Rural Class. by David Henderson (4612354)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Overview of study procedures. by Matthew G. Vinson (22593374)

“…VIDEO and CONTROL were associated with a similar rise in intent to decrease OTC NSAID use (1.92 (SD: 4.41) vs. 1.36 (SD: 3.46), p = 0.150) and a similar decrease in NSAIDs exposure (−32.8% in VIDEO and −36.5% in CONTROL, p = 0.520) 4 weeks post-intervention. …”

Relative Index of Inequality (RII) and 95% Confidence Interval (CI) for access question between most a least deprived SIMD decile by A) Age and sex B) Number of Health Issues and c... by David Henderson (4612354)

Subjects: